G1 Therapeutics Inc Stock Price, News & Analysis

G1 Therapeutics (GTHX) reported $31.3 million in net revenue from COSELA sales for 2022, marking a significant 182% growth from 2021. The company forecasts 2023 revenue guidance for COSELA between $50 million and $60 million. Notably, results from the Phase 3 PRESERVE 1 trial for metastatic colorectal cancer showed achievement of co-primary endpoints but raised concerns as early anti-tumor efficacy data favored the placebo group. G1 announced a 30% workforce reduction to extend its cash runway, alongside a leadership change with Jennifer Moses stepping down as CFO. The firm finished 2022 with $145.1 million in cash and equivalents.

G1 Therapeutics, Inc. (Nasdaq: GTHX) will have its CEO, Jack Bailey, speak on a Breast and Lung Cancer Panel at the Cowen 43rd Annual Health Care Conference on March 7th, 2023, at 10:30 AM EST. This event is significant for G1, a commercial-stage oncology company focused on developing therapies to improve cancer treatment.

The session will be webcasted and available on the company's Events & Presentations page. G1 Therapeutics is known for its product, COSELA® (trilaciclib), and is actively researching various solid tumors, including breast and lung cancers.

G1 Therapeutics (Nasdaq: GTHX) will hold a webcast and conference call on March 1, 2023, at 8:30 a.m. ET to discuss its corporate and financial results for Q4 and the full year of 2022. This marks an important update for investors. Participants can register for the call and access a live and archived webcast on the company's website, which will be available for 90 days post-event. G1 Therapeutics focuses on next-generation therapies for cancer, including its product COSELA (trilaciclib), and has an ongoing tumor-agnostic clinical development plan targeting various solid tumors.

G1 Therapeutics, Inc. (GTHX) announced topline results from its Phase 3 PRESERVE 1 trial, achieving significant co-primary endpoints by reducing severe neutropenia during treatment cycles. Specifically, severe neutropenia incidence was 1% for trilaciclib versus 20% for placebo (p<0.001). However, early anti-tumor efficacy data indicated that the placebo arm had a better overall response rate (61% vs. 50%). Consequently, management has decided to discontinue the trial. Despite the positive myeloprotection results, the company expressed disappointment over the efficacy outcomes.

Simcere Pharmaceutical Group and G1 Therapeutics announced the first prescription for COSELA (trilaciclib) in China, marking a pivotal milestone in cancer treatment. This first-in-class drug aims to reduce chemotherapy-induced myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients. The prescription was issued on January 28, 2023, just 908 days after the licensing agreement. COSELA is FDA and NMPA approved and has shown significant efficacy in improving patient tolerance during chemotherapy, addressing a critical need in China. The collaboration reflects a commitment to advancing cancer therapies globally.

On February 1, 2023, G1 Therapeutics (GTHX) announced the grant of stock options for 2,800 shares and 1,400 restricted stock units (RSUs) to a new employee as part of the Amended and Restated G1 Therapeutics 2021 Inducement Equity Incentive Plan. The stock options, priced at $8.16 per share, will vest over four years, with 25% vesting on the first anniversary of employment. The RSUs also follow a similar vesting schedule. This initiative is in compliance with Nasdaq's Listing Rule 5635(c)(4), aimed at attracting new talent to the biopharmaceutical company focused on cancer therapies.

G1 Therapeutics, a commercial-stage oncology company, will present at the virtual 2023 B. Riley Securities 3rd Annual Oncology Conference on January 19, 2023, at 11:30 AM EST. CEO Jack Bailey will be leading the corporate presentation. Investors and interested parties can access the presentation through the company’s Events & Presentations page. G1 Therapeutics focuses on advancing therapies for cancer, with their first product, COSELA® (trilaciclib), currently in use. The company is headquartered in Research Triangle Park, N.C.

G1 Therapeutics (GTHX) announced that initial results from the pivotal Phase 3 PRESERVE 1 trial in metastatic colorectal cancer (mCRC) are expected in February 2023. These results will assess the primary endpoint of myeloprotection in patients treated with trilaciclib alongside FOLFOXIRI and bevacizumab. Positive outcomes could lead to regulatory interactions for label expansion. In addition, five clinical trials throughout 2023 will evaluate trilaciclib's effects on myeloprotection, immune function, and anti-tumor efficacy in various cancer types, including triple negative breast cancer and bladder cancer.

G1 Therapeutics (GTHX) provided an update on the ongoing PRESERVE 3 trial, a Phase 2 study evaluating the combination of trilaciclib with chemotherapy and avelumab in patients with metastatic urothelial carcinoma. Initial findings revealed an objective response rate of 40.0% for trilaciclib versus 46.7% for the control. The trial continues under the recommendation of the data monitoring committee due to acceptable safety profiles. Further results, particularly on progression-free survival, are expected mid-2023, with the possibility of presenting at a medical meeting.